| Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting | European Urology | 2011 | 537 |
| First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Journal of Clinical Oncology | 2011 | 444 |
| Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience | Journal of Clinical Oncology | 2011 | 424 |
| Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study | Annals of Surgery | 2011 | 417 |
| Guidelines for the management of oesophageal and gastric cancer | Gut | 2011 | 404 |
| Germline mutations in RAD51D confer susceptibility to ovarian cancer | Nature Genetics | 2011 | 379 |
| β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation | Modern Pathology | 2011 | 264 |
| BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients | British Journal of Cancer | 2011 | 249 |
| EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT | Gut | 2011 | 230 |
| Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population | European Journal of Endocrinology | 2011 | 165 |
| Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic | Ca-A Cancer Journal for Clinicians | 2011 | 144 |
| Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial | Lancet Oncology, The | 2011 | 133 |
| Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients | Pain | 2011 | 131 |
| Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis | Clinical Genetics | 2011 | 118 |
| The changing therapeutic landscape of castration-resistant prostate cancer | Nature Reviews Clinical Oncology | 2011 | 118 |
| Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors | Journal of Clinical Oncology | 2011 | 98 |
| Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck | British Journal of Cancer | 2011 | 96 |
| Dose escalation for non-small cell lung cancer: analysis and modelling of published literature | Radiotherapy and Oncology | 2011 | 92 |
| Chemotherapy-induced neuropathic pain | Current Opinion in Supportive and Palliative Care | 2011 | 90 |
| A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer | Clinical Cancer Research | 2011 | 88 |
| Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI | Journal of Magnetic Resonance Imaging | 2011 | 85 |
| Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance | British Journal of Radiology | 2011 | 83 |
| Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis | Colorectal Disease | 2011 | 78 |
| Reply: ‘Hand pattern indicates risk of prostate cancer’ | British Journal of Cancer | 2011 | 78 |
| Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia | British Journal of Haematology | 2011 | 76 |
